Loading…
Alector, Inc. is projected to rise to $3.18 by 2027, a +44% move from its current price of $2.21. ALEC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.13 | $2.21 | $2.30 | +0.05% |
| May 30 | $2.10 | $2.21 | $2.33 | +0.09% |
| May 31 | $2.07 | $2.21 | $2.36 | +0.14% |
| Jun 1 | $2.06 | $2.21 | $2.39 | +0.19% |
| Jun 2 | $2.04 | $2.22 | $2.41 | +0.24% |
| Jun 3 | $2.02 | $2.22 | $2.43 | +0.28% |
| Jun 4 | $2.01 | $2.22 | $2.45 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.01 | $2.22 | $2.45 | +0.33% |
| Week 2 | $1.93 | $2.22 | $2.56 | +0.67% |
| Week 3 | $1.88 | $2.23 | $2.65 | +1.00% |
| Week 4 | $1.84 | $2.24 | $2.73 | +1.34% |
| Week 5 | $1.80 | $2.25 | $2.80 | +1.67% |
| Week 6 | $1.77 | $2.25 | $2.87 | +2.01% |
| Week 7 | $1.74 | $2.26 | $2.94 | +2.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alector, Inc. is a clinical stage biotechnology company focused on counteracting the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC is currently priced at $2.21 with a market capitalization of $245.37M and is ranked 3691. The stock trades with a bullish technical backdrop, yet the 2026 forecast shows a neutral start with an average price of $2.21 for the year. The long-term forecast, however, points to meaningful upside driven by multi-year growth in average price and higher maximums through 2050, culminating in an average of $20.63 and a maximum of $44.57 by 2050.
A major floor 24.6% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
The nearest ceiling, 22.4% above — a clean break opens room to run.
A major ceiling 34.7% above — clearing it would confirm fresh momentum.
Key ALEC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALEC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.19 | Buy | $2.19 | Buy |
| MA 10 | $2.18 | Buy | $2.20 | Buy |
| MA 20 | $2.26 | Sell | $2.24 | Sell |
| MA 50 | $2.30 | Sell | $2.25 | Sell |
| MA 100 | $2.14 | Buy | $2.16 | Buy |
| MA 200 | $2.12 | Buy | $2.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.26 | Neutral |
| Stoch RSI (14) | 68.98 | Neutral |
| CCI (20) | -25.20 | Neutral |
| Williams %R (14) | -58.97 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 5.24 | Buy |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 41.03 | Neutral |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 51.74 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 2.22 | Sell |
| ADX (14) | 11.48 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is labeled BULLISH with RSI(14) at 50. The 50-day simple moving average stands at $2.30, while the 200-day simple moving average sits at $2.11. Immediate support is at $2.05 and resistance at $2.70, framing a 30-day range from a low of $1.70 to a high of $2.87.
Annualized volatility is high at 80%, underscoring notable price fluctuation even within the bullish setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.53 | $2.21 | $3.64 | 0% | Neutral | |
| $2.43 | $3.18 | $4.45 | +44% | Bullish | |
| $2.82 | $3.84 | $5.63 | +74% | Bullish | |
| $2.93 | $4.12 | $6.26 | +86% | Bullish | |
| $2.69 | $3.90 | $6.11 | +76% | Bullish | |
| $2.96 | $4.40 | $7.07 | +99% | Bullish | |
| $3.33 | $5.08 | $8.37 | +130% | Bullish | |
| $4.04 | $6.30 | $10.61 | +185% | Bullish | |
| $4.59 | $7.33 | $12.60 | +232% | Bullish | |
| $4.65 | $7.60 | $13.29 | +244% | Bullish | |
| $6.44 | $11.66 | $22.00 | +428% | Bullish | |
| $10.13 | $22.14 | $46.55 | +902% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.53 | $2.21 | $2.62 | +0.00% |
| June 2026 | $1.88 | $2.23 | $2.71 | +0.72% |
| July 2026 | $1.93 | $2.31 | $2.86 | +3.67% |
| August 2026 | $2.07 | $2.51 | $3.15 | +8.57% |
| September 2026 | $2.11 | $2.58 | $3.27 | +2.79% |
| October 2026 | $2.08 | $2.55 | $3.27 | -1.08% |
| November 2026 | $2.15 | $2.65 | $3.43 | +3.89% |
| December 2026 | $2.24 | $2.78 | $3.64 | +5.12% |
Click any year to see its month-by-month ALEC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ALEC is projected to trade between $1.53 and $3.64, averaging $2.21 — a potential gain of 0% from today's $2.21. Price action looks broadly range-bound.
Alector, Inc.'s 2027 outlook centres on $3.18, within a $2.43 to $4.45 range. That is up +44% on the projected 2026 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ALEC could reach as high as $5.63, with a base case around $3.84 and support toward $2.82 — roughly +74% from $2.21. Momentum favours further upside here.
Expect ALEC to range from $2.93 to $6.26 through 2029. The $4.12 average target implies a +86% move from current prices. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ALEC price prediction for 2030 points to an average of $3.90 (low $2.69, high $6.11) — a potential gain of +76% on today's $2.21. Momentum favours further upside here.
In 2031, ALEC is projected to trade between $2.96 and $7.07, averaging $4.40 — a potential gain of +99% from today's $2.21. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Alector, Inc.'s 2032 outlook centres on $5.08, within a $3.33 to $8.37 range. That is up +16% on the projected 2031 average. That marks a +130% change versus current levels. Momentum favours further upside here.
By 2033, ALEC could reach as high as $10.61, with a base case around $6.30 and support toward $4.04 — roughly +185% from $2.21. Buyers look set to stay in control over this stretch.
Expect ALEC to range from $4.59 to $12.60 through 2034. The $7.33 average target implies a +232% move from current prices. That is up +16% on the projected 2033 average. Momentum favours further upside here.
The ALEC price prediction for 2035 points to an average of $7.60 (low $4.65, high $13.29) — a potential gain of +244% on today's $2.21. Buyers look set to stay in control over this stretch.
In 2040, ALEC is projected to trade between $6.44 and $22.00, averaging $11.66 — a potential gain of +428% from today's $2.21. That is up +53% on the projected 2035 average. Momentum favours further upside here.
Alector, Inc.'s 2050 outlook centres on $22.14, within a $10.13 to $46.55 range. That is up +90% on the projected 2040 average. That marks a +902% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALEC today (≈ 452.488688 ALEC) could be worth
$10,016.36
+$9,016.36 (+902%) by 2050 · US Dollar
Based on the average projected ALEC price of $22.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALECwould be worth at today's price.
$1,000 invested in ALEC on May 27, 2025 (≈ 793.6508 ALEC) would be worth
$1,753.97
+$753.97 (+75.4%) today · 1.75× · US Dollar
Based on a ALEC entry price of $1.26 vs. today's $2.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.12 | $1,042.45 | +4.2% |
| 1 month ago | $2.35 | $940.43 | -6.0% |
| 3 months ago | $2.56 | $863.28 | -13.7% |
| 6 months ago | $1.33 | $1,661.65 | +66.2% |
| 1 year ago | $1.26 | $1,753.97 | +75.4% |
| All time (5.0y) ago | $17.94 | $123.19 | -87.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALEC forecast.
Our base-case forecast reaches $4.40 around 2032.
Implied market cap at $4.40: $488.51M
Over the multi-year horizon, the forecast envisions a gradual rise in the average price from a 2026 baseline of $2.21 toward substantially higher levels later in the decade and into the 2030s and beyond. The 2027–2035 period shows consistent bullish sentiment with year-by-year averages rising from $3.17 (2027) to $7.31 (2035) and corresponding ROIs of 43.5, 74.6, 84.2, 70, 94.5, 121.3, 172.5, 222.8, and 230.7 respectively. By 2040, the average is projected to $11.14 with a ROI of 403.9, and by 2050 the average could reach $20.63 with a max of $44.57 and an ROI of 833.4, all while sentiment remains BULLISH.
The forecast highlights strong upside potential alongside higher risk and uncertainty inherent in longer-horizon projections. Drivers cited by the numbers include the asset’s ongoing biotechnology focus and the potential benefits reflected in the long-run bullish trajectory, while risks remain inherent to clinical-stage biotechnology investments and market dynamics.
Tap a question to reveal the answer.
2030: min $2.56, avg $3.76, max $5.98; ROI: 70; sentiment: BULLISH.
The forecast shows a bullish path beyond 2026, with 2027 avg $3.17, 2028 avg $3.86, 2029 avg $4.07, 2030 avg $3.76, 2040 avg $11.14, and 2050 avg $20.63, along with rising maximums and ROIs up to 833.4. As with all investments, these are estimates and not guarantees.
Yes. The 2033 forecast shows max $10.34, indicating a potential rise above $10 under the projected path.
Current price is $2.21 and market cap is $245.37M.
In 2050, the average price is forecast at $20.63 with a max of $44.57 and an ROI of 833.4; sentiment is BULLISH.
Alector, Inc. Community Discussion
0Share your Alector, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.